Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone
| Autor: | Irma Csanalosi, Edward Schweizer, Karl Rickels, Hack R. Chung, W. George Case |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male Patient Dropouts Personality Inventory medicine.drug_class Nonbenzodiazepine Population Buspirone Tranquilizer Arts and Humanities (miscellaneous) Double-Blind Method medicine Clorazepate Humans Prospective Studies education Clorazepate Dipotassium Psychiatric Status Rating Scales education.field_of_study Benzodiazepine Clinical Trials as Topic Drug Tolerance Anxiety Disorders Panic Substance Withdrawal Syndrome Psychiatry and Mental health Outcome and Process Assessment Health Care Anti-Anxiety Agents Anesthesia Patient Compliance Female Psychology medicine.drug Buspirone hydrochloride |
| Zdroj: | Archives of general psychiatry. 45(5) |
| ISSN: | 0003-990X |
| Popis: | Risk of withdrawal was investigated in a prospective, double-blind comparison of clorazepate dipotassium, a benzodiazepine with a long half-life, and the nonbenzodiazepine buspirone hydrochloride in the long-term treatment of anxious outpatients. Patients were treated with therapeutic doses of clorazepate dipotassium (15 to 60 mg/d) or buspirone hydrochloride (10 to 40 mg/d) for six continuous months before their tranquilizer therapy was blindly and abruptly stopped. There was a significant increase in symptom severity consistent with a withdrawal reaction for the clorazepate group but not the buspirone group. For the clorazepate group, there was a suggestion that previous discontinuous exposure to benzodiazepines might sensitize patients to subsequent withdrawal effects. For the buspirone group, a higher dropout rate raised questions about patient satisfaction with therapy in this rather chronically anxious population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|